Cystic Fibrosis Patients Showed Significant Improvement With HP-3
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Cystic Fibrosis Patients Showed Significant Improvement With HP-3

BOXFORD, MA. -- December 13, 1999 -- Milkhaus Laboratory, Inc. announced that a Phase II clinical trial of its product, HP-3, was successful in treating patients with cystic fibrosis. The results showed significant improvement in pulmonary function and an increase in sputum clearance.

Cystic fibrosis is a chronic, inherited disease of the exocrine glands that affects children and young adults. Thick mucus builds up in the lungs which severely limits pulmonary function and the ability to carry out normal activities of living. Chronic lung infections are common and damage to lung tissue occurs as a result of inflammation and chronic oxygen deprivation. There is no effective treatment for the disease. Products currently available offer only nominal improvements in symptoms for the 35,000 patients in the U.S.

Commenting on this trial, the Company's CEO, Dr. John McMichael, said: "Our cystic fibrosis trial was one of three we conducted using HP-3 in patients with diseases involving respiratory distress caused by sputum or scar tissue blocking the airways. The other trials were in chronic bronchitis and chronic obstructive pulmonary disease, or COPD. In all three, HP-3 increased sputum expectoration and significantly improved pulmonary function. We believe it evokes such responses through a mechanism common to all three disease categories. As a result, the product has very broad potential utility in relieving the debilitating symptoms of respiratory distress which afflict more than 15 million people in the U.S. Furthermore, results suggest that it does so safely and without the need to limit the use of other medications."

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities